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The traditional view of recovery following acute kidney 
injury (AKI) was that patients who successfully overcame 
the severe illness underlying their AKI would experience 
a full restoration of their premorbid kidney function. 
Recent work has suggested that patients who survived an 
episode of AKI are at ongoing risk of adverse outcomes. 
These include de novo chronic kidney disease (CKD), 
progression of pre-existing CKD, end-stage kidney dis-
ease (ESRD), and death [1–4]. With a greater apprecia-
tion of the fact that AKI survivors often have a challeng-
ing clinical course, healthcare providers and researchers 
must establish practical definitions to cover the full spec-
trum of post-AKI kidney outcomes.
While ESRD reflects the extreme end of the CKD 
spectrum and fortunately affects a minority of AKI sur-
vivors, progressive non-dialysis requiring CKD is a far 
more frequent outcome following an episode of AKI. 
The incidence of progressive CKD in AKI survivors may 
be underestimated partly because kidney function is not 
routinely monitored in structured follow-up programs 
[5]. This is further limited by the existence of variable 
definitions for kidney recovery. Finally, even when serial 
assessments of kidney function are available, reliance 
on creatinine as a marker of glomerular filtration rate 
(GFR) risks overestimating renal function shortly after 
an acute illness during which muscle wasting might have 
occurred. Prowle and co-workers demonstrated that a 
potential 135% increase in CKD diagnoses when adjust-
ing for the confounding effect of prolonged major illness 
on the serum creatinine concentration [6].
Data from large registries have shed some light on the 
risk of CKD following critical illness that was compli-
cated by AKI. In a cohort of 130,134 critically ill patients 
from the Swedish Intensive Care Register from 2005 to 
2011, followed for 1–7 years, the relative risks of de novo 
CKD and ESRD after an episode of AKI (patients with 
pre-admission CKD excluded) were 7- and 22-fold higher 
as compared to patients who did not experience AKI 
[7]. The incidence of CKD was 6.0% (95% CI 5.1–7.0) at 
1 year and 10.5% (95% CI 8.5–13.0) at 5 years, with ESRD 
occurring in 0.44% (95% CI 0.18–0.24) and 1.8% (95% CI 
1.6–1.9) at corresponding time points. This confirms data 
from prior studies that have demonstrated an association 
between AKI and subsequent CKD, whereby CKD devel-
ops in 20–40% of AKI survivors [8–10].
Numerous factors impact the trajectory of kidney func-
tion after an episode of AKI. Prompt recovery of AKI 
anticipates a lower likelihood of CKD as compared to a 
slower recovery [11]. In a cohort of 17,000 patients, the 
authors observed five patterns of recovery following an 
initial episode of AKI: early reversal, with kidney func-
tion sustained to discharge (26.6%); no reversal at all 
(26.5%); late reversal after day  7 (9.7%); early reversal 
with relapse/relapses but ultimate recovery (22.5%); and 
relapse without recovery (14.7%) [11]. Schiffl and Fis-
cher demonstrated that 26% of AKI survivors with non-
recovery of kidney function at discharge improved renal 
function and 10.7% returned to a normalized estimated 
GFR; all changes took place within the first year [12]. A 
study of hospitalized patients described a return to base-
line creatinine in 92.5%, partial recovery in 7%, and no 
recovery in 0.6% of patients 3 months after AKI. Patients 
with RIFLE F had significantly lower rates of recovery 
(p < 0.001) [13].
The Acute Disease Quality Initiative (ADQI) group 
has developed consensus definitions for renal recovery 
after AKI (Fig.  1). The new proposed definitions differ-
entiate rapid recovery from delayed recovery and pro-
vide a framework for staging the post-AKI/pre-CKD 
period. Once validated, this proposed scheme could help 
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standardize the nomenclature of kidney recovery and 
enable the design of robust trials that examine kidney 
recovery as an outcome in trials testing various candidate 
interventions [14].
The optimal follow-up of AKI survivors remains con-
troversial. In a cohort of patients discharged from hospi-
tal after an episode of dialysis-requiring AKI, Harel et al. 
showed that only a minority of patients visited a nephrolo-
gist in the weeks following their hospitalization; however, 
there was an association between visiting a nephrologist 
and improved survival [15]. Though it might seem intui-
tive to extend early nephrology follow-up to all survi-
vors of non-dialysis requiring AKI, the high incidence 
of hospital-associated AKI would make this impracti-
cable. Moreover, many AKI survivors will have a benign 
clinical course suggesting that more targeted selection 
of high-risk patients is required. At present, there is lim-
ited information to predict adverse outcomes in AKI sur-
vivors and a biomarker that could reliably predict such 
outcomes would be of high value to clinicians. Dedicated 
clinics for the follow-up of AKI survivors have been estab-
lished at some centers [16]. An ongoing multicenter pilot 
trial in Canada is randomizing survivors of AKI (KDIGO 
stage  2 or higher) to follow-up in a dedicated post-AKI 
clinic for 1 year as compared to usual care [Clinicaltrials.
gov NCT02483039]. As we await the findings of this trial 
more research is needed to clarify the most impactful 
components of care delivery in such clinics.
In the meantime we suggest that patients with severe 
AKI, KDIGO stage 3 and certainly those who received 
renal replacement therapy, receive targeted follow-up 
with a nephrologist within 30 days of hospital discharge 
with further follow-up individualized to the patient’s 
needs. Such follow-up should comprise a reassessment of 
kidney function/kidney damage, attention to blood pres-
sure control and cardiovascular risk factors, medication 
reconciliation, and patient education regarding the impli-
cations of a prior AKI episode.
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Fig. 1 Hypothetical trajectories of acute kidney disease (AKD). AKD follows on from acute kidney injury (AKI) in those patients who do not fully 
recover within 7 days. The trajectory of AKD can take many forms largely depending on the severity of the initial AKI episode. Here, a series of 
hypothetical scenarios representing typical trajectories of the AKI–AKD continuum are depicted. Stage 3 AKI might slowly improve to stage 2 AKI 
and then progress to AKD (1). Stage 1 AKI might progress to stage 3, then improve rapidly to stage 1 AKI before progressing to stage 1 AKD (2). 
An episode of persistent AKI (>48 h) might be followed by a period of sustained reversal (asterisks), then a second episode of AKI (double dagger) 
leading to AKD (3). Stage 2 AKI might rapidly reverse (4). Subacute AKD might occur wherein the first 7 days are marked with slowly worsening renal 
function that does not technically meet the criteria for AKI, and progress to Stage 3 AKD (5). This trajectory can be seen in patients treated with 
chronic nephrotoxic medications (e.g., with aminoglycosides) Modified from Acute Dialysis Quality Initiative 16; www.adqi.org
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